From Conception to Revelation: Non-Invasive Prenatal Testing Explored

Zhilei  Chen; Baichuan Wang; Yishan Yuan; Luhan Zhang

doi:10.62051/78ajvf27

Authors

Zhilei Chen
Baichuan Wang
Yishan Yuan
Luhan Zhang

DOI:

https://doi.org/10.62051/78ajvf27

Keywords:

Non-Invasive prenatal sequencing; Next Generation Sequencing; massive parallel sequencing; genetic disorder; cell-free fetal DNA; Microarrays.

Abstract

Prenatal testing plays a crucial role in addressing the inherent unpredictability of genetic disorders that can affect unborn children. Non-Invasive Prenatal Testing (NIPT) has emerged as a groundbreaking tool in the realm of prenatal care, enabling the early detection of chromosomal abnormalities. By examining fetal DNA present in the mother's bloodstream, NIPT has achieved remarkable accuracy rates, surpassing invasive techniques that carry inherent risks. However, with these advancements come ethical considerations. The results of NIPT can significantly influence a mother's decision regarding the continuation or termination of pregnancy. This decision can be further complicated by religious beliefs, which often play a pivotal role in guiding choices related to pregnancy. Moreover, receiving a positive result from NIPT can subject expectant mothers to profound emotional stress, highlighting the need for comprehensive counseling and support services. In addition to these ethical concerns, practical limitations persist. The cost of NIPT remains a substantial barrier for many families, potentially limiting its accessibility. Furthermore, NIPT's accuracy can be influenced by factors such as gestational age, with tests often yielding inconclusive results when fetal fractions are low. Despite these challenges, technological innovations, including microarrays and Next Generation Sequencing (NGS), have bolstered the capabilities of NIPT. These advancements enable a more comprehensive assessment of fetal DNA, enhancing the overall quality of prenatal care. As NIPT continues to evolve and integrate with broader genomic technologies, society must engage in thoughtful reflection on its implications. The potential normalization of pregnancy terminations based on genetic information underscores the importance of ethical and societal discussions surrounding the use of NIPT, with a focus on preserving informed patient choices and ensuring comprehensive support for expectant parents facing difficult decisions.

Downloads

Download data is not yet available.

References

G. de Graaf, F. Buckley, and B. G. Skotko, “Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States,” Am J Med Genet A, vol. 167, no. 4, pp. 756 – 767, Apr. 2015.

B. Orr, K. M. Godek, and D. Compton, “Aneuploidy,” Current Biology, vol. 25, no. 13, pp. R538 – R542, Jun. 2015.

I. Dumitru Suciu, O. Daniela Toader, S. Galeva, and L. Pop, “Non-Invasive Prenatal Testing beyond Trisomies,” J Med Life, vol. 12, no. 3, pp. 221 – 224, Jul. 2019.

H. Zhang et al., “Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146 958 pregnancies,” Ultrasound in Obstetrics & Gynecology, vol. 45, no. 5, pp. 530 – 538, May 2015.

P. Benn, H. Cuckle, and E. Pergament, “Non-invasive prenatal testing for aneuploidy: current status and future prospects,” Ultrasound in Obstetrics & Gynecology, vol. 42, no. 1, pp. 15 – 33, Jul. 2013.

K. R. M. van der Meij et al., “Routinization of prenatal screening with the non-invasive prenatal test: pregnant women’s perspectives,” European Journal of Human Genetics, vol. 30, no. 6, pp. 661 – 668, 2022.

Y. M. D. Lo et al., “Presence of fetal DNA in maternal plasma and serum,” The Lancet, vol. 350, no. 9076, pp. 485 – 487, Aug. 1997.

L. Carbone et al., “Non-Invasive Prenatal Testing: Current Perspectives and Future Challenges,” Genes (Basel), vol. 12, no. 1, 2021.

T. K. Lau et al., “Clinical utility of noninvasive fetal trisomy (NIFTY) test – early experience,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 25, no. 10, pp. 1856 – 1859, Oct. 2012.

B. Bruijns, R. Tiggelaar, and H. Gardeniers, “Massively parallel sequencing techniques for forensics: A review,” Electrophoresis, vol. 39, no. 21, pp. 2642 – 2654, Nov. 2018.

J. Reinartz et al., “Massively parallel signature sequencing (MPSS) as a tool for in-depth quantitative gene expression profiling in all organisms,” Brief Funct Genomics, vol. 1, no. 1, pp. 95 – 104, Feb. 2002.

A. Thapar and M. Cooper, “Copy Number Variation: What Is It and What Has It Told Us About Child Psychiatric Disorders?,” J Am Acad Child Adolesc Psychiatry, vol. 52, no. 8, pp. 772 – 774, Aug. 2013.

C. Turchi, F. Melchionda, M. Pesaresi, and A. Tagliabracci, “Evaluation of a microhaplotypes panel for forensic genetics using massive parallel sequencing technology,” Forensic Sci Int Genet, vol. 41, pp. 120 – 127, 2019.

J. Gordevičius et al., “Identification of fetal unmodified and 5-hydroxymethylated CG sites in maternal cell-free DNA for non-invasive prenatal testing,” Clin Epigenetics, vol. 12, no. 1, p. 153, 2020.

M. Mortarino, A. Franceschi, F. Mancianti, C. Bazzocchi, C. Genchi, and C. Bandi, “[Quantitative PCR in the diagnosis of Leishmania],” Parassitologia, vol. 46, no. 1 – 2, pp. 163 – 167, 2004, [Online].

P. Brady et al., “Clinical implementation of NIPT – technical and biological challenges,” Clin Genet, vol. 89, no. 5, pp. 523 – 530, May 2016.

M. Badeau et al., “Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women,” Cochrane Database of Systematic Reviews, vol. 2017, no. 11, Nov. 2017.

T. McKanna et al., “Fetal fraction-based risk algorithm for non-invasive prenatal testing: screening for trisomies 13 and 18 and triploidy in women with low cell-free fetal DNA,” Ultrasound in Obstetrics & Gynecology, vol. 53, no. 1, pp. 73 – 79, Jan. 2019.

M. Dufva, “Introduction to Microarray Technology,” in DNA Microarrays for Biomedical Research: Methods and Protocols, M. Dufva, Ed., Totowa, NJ: Humana Press, 2009, pp. 1 – 22.

K. Juneau et al., “Microarray-Based Cell-Free DNA Analysis Improves Noninvasive Prenatal Testing,” Fetal Diagn Ther, vol. 36, no. 4, pp. 282 – 286, Sep. 2014.

H. P. J. Buermans and J. T. den Dunnen, “Next generation sequencing technology: Advances and applications,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1842, no. 10, pp. 1932 – 1941, 2014.

A. de Jong, W. J. Dondorp, C. E. M. de Die-Smulders, S. G. M. Frints, and G. M. W. R. de Wert, “Non-invasive prenatal testing: ethical issues explored,” European Journal of Human Genetics, vol. 18, no. 3, pp. 272 – 277, 2010.